Margaret R. Dalesandro, Ph.D.
Margaret R. Dalesandro, Ph.D., is an accomplished biopharmaceutical executive with over 30 years of experience in drug development and commercialization. She is currently president of Brecon Pharma Consulting LLC, which she founded in 2012. Previously, Dr. Dalesandro held senior executive leadership positions contributing significantly to the approval of groundbreaking drugs, including in the fields of oncology, cardiology, inflammation, and ophthalmology. As vice president and founder of the project, portfolio, and alliance management team at ImClone Systems, she managed the successful development of ERBITUX (anti-EGFR) and the other oncology portfolio products including CYRAMZA (anti-VEGFR2), which contributed to the $6.5 billion sale of ImClone Systems to Eli Lilly in 2008. Prior to this, Dr. Dalesandro served as executive director of global product strategy and product/portfolio management at GlaxoSmithKline PLC. Dr. Dalesandro spent the early years of her career as Director of Immunobiology and Diagnostic research at Centocor, Inc. (now a subsidiary of Johnson & Johnson) where she contributed significantly to the successful development of REMICADE (Infliximab), a first in class antibody for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis and Crohn’s disease. She is currently a member of the boards of directors of Seelos Therapeutics and Skye Biosciences.
Dr. Dalesandro holds M.A. and Ph.D. degrees in biochemistry from Bryn Mawr College and completed a National Institutes of Health postdoctoral fellowship in molecular immunology at Wake Forest University.